Literature DB >> 33991527

Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach.

Adam S Fisch1, Israa Laklouk1, Masato Nakaguro1, Vânia Nosé1, Lori J Wirth2, Daniel G Deschler3, William C Faquin4, Dora Dias-Santagata1, Peter M Sadow5.   

Abstract

After the publication of the 2017 World Health Organization Classification of Head and Neck Tumours, there has been increasing interest in the classification of newly categorized intraductal carcinomas. Intraductal carcinoma (IC) is an indolent tumor, typically arising in the parotid gland, with an intact myoepithelial layer and a cystic, papillary, often cribriform architecture. Early studies of IC identified a heterogeneous group of molecular alterations driving neoplasia, and recent studies have defined three primary morphological/immunohistochemical variants, subsequently linking these morphologic variants with defined molecular signatures. Although studies to date have pointed toward distinct molecular alterations after histological classification, this study used a novel approach, focusing primarily on six cases of IC with NCOA4-RET gene rearrangement as determined by next-generation sequencing and describing the spectrum of clinicopathologic findings within that molecularly-defined group, among them a unique association between the NCOA4-RET fusion and hybrid variant IC and the first case of IC arising in association with a pleomorphic adenoma. RET-rearranged IC show histological and immunohistochemical overlap with the more widely recognized secretory carcinoma, including low-grade morphology, a lumen-forming or microcystic growth pattern, and co-expression of S100, SOX10, and mammaglobin, findings undoubtedly leading to misdiagnosis. Typically regarded to have ETV6-NTRK3 fusions, secretory carcinomas may alternatively arise with RET fusions as well. Adding our cohort of six NCOA4-RET fusion-positive IC compared with four cases of secretory carcinoma with ETV6-RET fusions and a single case of fusion-negative IC with salivary duct carcinoma-like genetics, we propose a diagnostic algorithm that integrates histological elements, including atypia and invasiveness, and the likelihood of specific molecular alterations to increase diagnostic accuracy in what can be a very subtle diagnosis with important clinical implications.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ETV6-RET; Intraductal carcinoma; NCOA4-RET; Salivary gland carcinoma; Secretory carcinoma

Mesh:

Substances:

Year:  2021        PMID: 33991527      PMCID: PMC9377626          DOI: 10.1016/j.humpath.2021.05.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.526


  51 in total

1.  Intraductal Carcinoma of Salivary Gland Originating from an Intraparotid Lymph Node: A Case Report.

Authors:  S C Lin; R T Ko; B H Kang; J S Wang
Journal:  Malays J Pathol       Date:  2019-08       Impact factor: 0.656

2.  Low-grade intraductal carcinoma of the salivary gland with prominent oncocytic change: a newly described variant.

Authors:  Masato Nakaguro; Makoto Urano; Hiroaki Suzuki; Kazuyuki Yamada; Asumi Sakaguchi; Kanako Ogura; Toshiharu Matsumoto; Noritsugu Ono; Tsuguharu Asato; Yoshiki Mikami; Hiroshi Imai; Toshitaka Nagao
Journal:  Histopathology       Date:  2018-05-21       Impact factor: 5.087

3.  Intraductal carcinoma of the minor salivary gland.

Authors:  K T Chen
Journal:  J Laryngol Otol       Date:  1983-02       Impact factor: 1.469

Review 4.  Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity.

Authors:  Alena Skalova
Journal:  Head Neck Pathol       Date:  2013-07-03

5.  Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study.

Authors:  Todd M Stevens; Andra O Kovalovsky; Claudia Velosa; Qiuying Shi; Qian Dai; Randall P Owen; Walter C Bell; Shi Wei; Pamela A Althof; Jennifer N Sanmann; Larissa Sweeny; William R Carroll; Gene P Siegal; Martin J Bullock; Margaret Brandwein-Gensler
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

6.  Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors.

Authors:  Zheng Zhao; Tao Fu; Jiyue Gao; Yang Xu; Xue Wu; Wenjuan Chen; Xuesong Li; Ruoying Yu; Yang Washington Shao; Man Li; Yu Yao
Journal:  J Med Genet       Date:  2020-04-13       Impact factor: 6.318

7.  RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.

Authors:  Shumei Kato; Vivek Subbiah; Erica Marchlik; Sheryl K Elkin; Jennifer L Carter; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

8.  Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.

Authors:  Alena Skálová; Tomas Vanecek; Emmanuelle Uro-Coste; Justin A Bishop; Ilan Weinreb; Lester D R Thompson; Stefano de Sanctis; Marco Schiavo-Lena; Jan Laco; Cécile Badoual; Thalita Santana Conceiçao; Nikola Ptáková; Martina Baněčkova; Marketa Miesbauerová; Michal Michal
Journal:  Am J Surg Pathol       Date:  2018-11       Impact factor: 6.394

9.  Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma.

Authors:  Akeesha A Shah; Bruce M Wenig; Robin D LeGallo; Stacey E Mills; Edward B Stelow
Journal:  Head Neck Pathol       Date:  2014-07-31

10.  GSDS 2.0: an upgraded gene feature visualization server.

Authors:  Bo Hu; Jinpu Jin; An-Yuan Guo; He Zhang; Jingchu Luo; Ge Gao
Journal:  Bioinformatics       Date:  2014-12-10       Impact factor: 6.937

View more
  2 in total

1.  Cytomorphologic features of intraductal salivary gland carcinoma: A multi-institutional study of 13 FNA cases with histologic, molecular, and clinical correlations.

Authors:  Kartik Viswanathan; Peter M Sadow; Zahra Maleki; Michiya Nishino; Zubair W Baloch; Todd E Abbott; Rema Rao; William C Faquin
Journal:  Cancer Cytopathol       Date:  2021-10-01       Impact factor: 4.264

Review 2.  RET signaling pathway and RET inhibitors in human cancer.

Authors:  Angelina T Regua; Mariana Najjar; Hui-Wen Lo
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.